Rana McKay, MD, presents the case of a 73-year-old man with advanced renal cell carcinoma, shares her initial impression, and reviews which factors contribute to a patient’s risk status.
A 73-Year-Old Man with Advanced Renal Cell Carcinoma
Dr Rana McKay discusses the efficacy and qualify-of-life data from the 5-year follow-up of the CheckMate 214 trial investigating nivolumab plus ipilimumab in frontline advanced renal cell carcinoma treatment.
Dr Rana McKay reviews key efficacy data from the COSMIC 313 trial and discusses factors that are considered when choosing between IO-TKI or IO-IO combinations.
Dr Rana McKay discusses the rationale for using cabozantinib with nivolumab and ipilimumab in the COSMIC 313 trial and reviews the adverse events seen with this combination in the COSMIC 313 trial.
Rana McKay, MD, shares advice for community oncologists treating patients with advanced renal cell carcinoma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
